Michelson Diagnostics’ Dynamic OCT Imaging Technology reveals changes in Skin Blood Vessels in Real-Time

Data Published in The Journal of the European Academy of Dermatology and Venereology (JEADV)

Maidstone, UK, 26 February 2016 – Michelson Diagnostics, a medical device company focused on applications of multi-beam Optical Coherence Tomography (‘OCT’) technology, today announces data showing that its Dynamic OCT imaging technology is able to visualise in real-time the structure of blood vessels beneath the surface of the skin, and the real-time effects of a therapeutic agent on this vasculature. This breakthrough imaging development has the potential to assist dermatologists in the detection and prognosis of melanoma as well as monitoring the effectiveness of treatments for multiple skin conditions, including port wine stains, rosacea, photo-aged skin and scars.

“This significant achievement provides dermatologists with images containing a wealth of information previously unavailable using existing scanning techniques. By integrating the Dynamic OCT technology with our VivoSight point-of-care scanner, we have significantly expanded our potential market segments,” noted Andy Hill, CEO of Michelson Diagnostics. “The study conducted by our colleagues at Roskilde Hospital in Denmark clearly demonstrates the power of Dynamic OCT in visualising blood vessel structures and changes to their appearance following a treatment. Multiple clinical studies continue to further explore the potential of this medical imaging advance.

Data from this validation study, published in The Journal of the European Academy of Dermatology and Venereology, showed statistically significant changes before and after application of brimonidine tartrate (Mirvaso®, Galderma), which correlated with measurements made with other devices (chromametry, LSCI). In 25 of 31 subjects (81%) successfully imaged, Dynamic OCT images showed a distinct change in the pattern of facial blood vessels before-and-after brimonidine. The images showed that after the application of brimonidine, smaller vessels ceased to be visible, leaving only the large and medium sized vessels to be recognized. Furthermore, the remaining larger-sized vessels were found to have a reduced diameter.

“Dynamic OCT brings an entirely new dimension to skin imaging. This new tool will allow us, for the first time, to see blood vessel structures, and changes to them produced by therapeutic agents, in vivo, which is a significant advancement in skin imaging and tissue visualisation,” explained author Professor Gregor Jemec, Professor and Chairman at the Department of Dermatology, Roskilde Hospital, Copenhagen, Denmark. “Until now, it has been very difficult to know precisely if a treatment for certain skin complaints has been effective and can be stopped. This technology has the potential to allow us to monitor treatment and show our patients the results in real-time in a similar way to ultrasound and X-ray images.”

For further information

Michelson Diagnostics Tel: +44 (0)20 8308 1695
Andy Hill, Chief Executive Officer  

Notes to editors

Study Summary:

A total of 35 healthy participants (9 men, 26 women) from three European clinical dermatology centres were included in the study. The median age was 30 years (23 – 60) and the skin types varied from I-IV on the Fitzpatrick scale. The included participants did not have active skin disease. In vivo images of the microcirculation in the skin were acquired using the built-in ‘Dynamic OCT’ option of the VivoSight OCT system. ‘Dynamic OCT’ detects areas of motion in the scanned image which were attributed to blood flow by the study authors. Images were taken of a skin area measuring 6×6 mm and a depth of 2mm.

About the VivoSight OCT System and Michelson Diagnostics

Michelson Diagnostics develops, manufactures and markets the VivoSight multi-beam Optical Coherence Tomography (‘OCT’) scanner, a point-of-care, real-time, non-invasive tissue-imaging device. The patented technology, which has CE/TGA regulatory-clearance and FDA 510(k) clearance in the United States, provides clinicians with continuous images of the epidermis and superficial dermis of the skin that can be interpreted by a trained medical professional to aid their assessment of the patient’s condition. Given the unprecedented image resolution and image quality, VivoSight OCT has many potential clinical applications beyond the initial focus in dermatology. The ‘Dynamic OCT’ technology is a software add-on and has CE regulatory clearance; FDA 510(k) clearance is currently pending.

The Company’s vision is for the VivoSight OCT system to become the standard-of-care for the non-invasive diagnosis and treatment monitoring of certain diseases and conditions that affect cutaneous and epithelial linings of the body. Michelson Diagnostics currently generates revenues from the first commercial application of VivoSight, in the diagnosis of non-melanoma skin cancer (NMSC).

Michelson Diagnostics, based in Maidstone, Kent, was founded in 2006 and has 16 employees, and has offices in Germany and USA. It is supported by syndicate of venture capital, corporate and private investors, including funds managed by Octopus Investments, Smith and Nephew, Catapult Ventures and Angel Investors.

For more information about Michelson Diagnostics and the VivoSight system, see www.vivosight.com.